Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$305.70 -0.4%	$303.16	$253.30 ▼ $346.85	$164.22B	0.53	2.70 million shs	1.91 million shs
GILD Gilead Sciences	$111.89 +0.5%	$106.63	$62.07 ▼ $119.96	$138.56B	0.32	7.28 million shs	7.44 million shs
MRNA Moderna	$27.72 +2.1%	$34.21	$26.26 ▼ $170.47	$10.72B	1.86	6.92 million shs	11.79 million shs
REGN Regeneron Pharmaceuticals	$625.60 +1.4%	$680.43	$605.56 ▼ $1,211.20	$68.39B	0.27	676,916 shs	899,886 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-0.40%	0.00%	-1.63%	+17.90%	+10.68%
GILD Gilead Sciences	+0.55%	+2.40%	-3.53%	+21.78%	+55.21%
MRNA Moderna	+2.06%	-11.94%	-8.42%	-34.00%	-73.25%
REGN Regeneron Pharmaceuticals	+1.39%	-2.27%	-8.65%	-12.53%	-34.47%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.4467 of 5 stars	2.2	4.0	3.3	3.9	3.6	2.5	0.6
GILD Gilead Sciences	4.601 of 5 stars	2.4	4.0	1.7	4.1	3.5	2.5	1.9
MRNA Moderna	4.3671 of 5 stars	4.0	1.0	0.0	4.6	1.9	2.5	1.3
REGN Regeneron Pharmaceuticals	4.8218 of 5 stars	4.4	3.0	1.7	2.3	3.9	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.48	Hold	$314.04	2.73% Upside
GILD Gilead Sciences	2.72	Moderate Buy	$105.12	-6.05% Downside
MRNA Moderna	2.04	Hold	$59.00	112.84% Upside
REGN Regeneron Pharmaceuticals	2.76	Moderate Buy	$966.88	54.55% Upside

Current Analyst Ratings Breakdown

Latest AMGN, REGN, GILD, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/31/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$1,100.00 ➝ $1,000.00
3/27/2025	GILD Gilead Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$120.00 ➝ $130.00
3/21/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$40.00 ➝ $33.00
3/13/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
3/11/2025	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$123.00 ➝ $130.00
3/5/2025	AMGN Amgen	Johnson Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$294.00
3/5/2025	AMGN Amgen	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$275.00 ➝ $294.00
3/5/2025	GILD Gilead Sciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$116.00 ➝ $126.00
3/5/2025	GILD Gilead Sciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$120.00 ➝ $140.00
3/4/2025	GILD Gilead Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$115.00 ➝ $132.00
2/19/2025	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$96.00 ➝ $78.00

(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.91	$30.63 per share	9.98	$10.93 per share	27.97
GILD Gilead Sciences	$28.75B	4.85	$8.84 per share	12.66	$15.44 per share	7.25
MRNA Moderna	$3.20B	3.35	N/A	N/A	$28.33 per share	0.98
REGN Regeneron Pharmaceuticals	$14.20B	4.82	$41.08 per share	15.23	$268.50 per share	2.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$7.55	40.49	14.29	2.63	12.24%	176.32%	11.71%	5/1/2025 (Estimated)
GILD Gilead Sciences	$480M	$0.37	302.41	13.80	0.71	1.67%	31.63%	10.38%	4/24/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$38.28	16.34	16.45	2.34	31.07%	16.32%	12.76%	4/29/2025 (Estimated)

Latest AMGN, REGN, GILD, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	AMGN Amgen	$4.18	N/A	N/A	N/A	$8.05 billion	N/A
5/1/2025	N/A	MRNA Moderna	-$2.90	N/A	N/A	N/A	$130.35 million	N/A
4/29/2025	N/A	REGN Regeneron Pharmaceuticals	$8.83	N/A	N/A	N/A	$3.40 billion	N/A
4/24/2025	N/A	GILD Gilead Sciences	$1.73	N/A	N/A	N/A	$6.77 billion	N/A
2/11/2025	Q4 2024	GILD Gilead Sciences	$1.67	$1.90	+$0.23	$1.42	$7.15 billion	N/A
2/4/2025	Q4 2024	AMGN Amgen	$5.04	$5.31	+$0.27	$1.16	$8.87 billion	N/A
2/4/2025	Q4 24	REGN Regeneron Pharmaceuticals	$11.21	$12.07	+$0.86	$8.06	$3.76 billion	$3.79 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.11%	+8.53%	126.09%	14 Years
GILD Gilead Sciences	$3.16	2.82%	+2.74%	854.05%	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$0.88	0.14%	N/A	2.30%	N/A

Latest AMGN, REGN, GILD, and MRNA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/4/2025	AMGN Amgen	quarterly	$2.38	3.05%	5/16/2025	5/16/2025	6/6/2025
2/5/2025	GILD Gilead Sciences	quarterly	$0.79	3%	3/14/2025	3/14/2025	3/28/2025
2/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.53%	2/20/2025	2/20/2025	3/20/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	9.62	1.26	0.95
GILD Gilead Sciences	1.24	1.50	1.20
MRNA Moderna	N/A	3.67	3.62
REGN Regeneron Pharmaceuticals	0.09	4.73	3.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
GILD Gilead Sciences	83.67%
MRNA Moderna	75.33%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
GILD Gilead Sciences	0.16%
MRNA Moderna	11.00%
REGN Regeneron Pharmaceuticals	7.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.21 million	533.50 million	Optionable
GILD Gilead Sciences	17,000	1.25 billion	1.24 billion	Optionable
MRNA Moderna	3,900	386.62 million	324.40 million	Optionable
REGN Regeneron Pharmaceuticals	11,900	109.33 million	101.15 million	Optionable

AMGN, REGN, GILD, and MRNA Headlines

Recent News About These Companies

Geode Capital Management LLC Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 3 at 5:55 AM | marketbeat.com

Gilead, Regeneron have most theoretical PDUFA date risk, says BofA

April 3 at 4:17 AM | markets.businessinsider.com

Is Regeneron Pharmaceuticals, Inc. (REGN) The Most Profitable Biotech Stock To Buy Right Now?

April 2 at 10:30 AM | insidermonkey.com

Groupama Asset Managment Has $56.45 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 2 at 7:06 AM | marketbeat.com

Trexquant Investment LP Acquires 42,674 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 2 at 6:46 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Alliancebernstein L.P.

April 2 at 5:33 AM | marketbeat.com

Schroder Investment Management Group Sells 13,477 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 2 at 4:49 AM | marketbeat.com

WINTON GROUP Ltd Sells 755 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 2 at 4:07 AM | marketbeat.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week Low on Analyst Downgrade

April 1 at 11:12 AM | marketbeat.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,000.00 at JPMorgan Chase & Co.

April 1 at 10:56 AM | marketbeat.com

RFK Jr. 'needs a lot of help and expertise' on science, says Regeneron CEO

April 1 at 10:02 AM | youtube.com

Franklin Resources Inc. Has $1.46 Billion Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 1 at 7:09 AM | marketbeat.com

Cannell & Spears LLC Has $11.44 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 1 at 6:49 AM | marketbeat.com

Summit Financial LLC Has $7.50 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 1 at 6:39 AM | marketbeat.com

AIA Group Ltd Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 1 at 6:01 AM | marketbeat.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $1,000.00 by Analysts at JPMorgan Chase & Co.

April 1 at 2:39 AM | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 12-Month Low After Analyst Downgrade

April 1 at 1:23 AM | americanbankingnews.com

Regeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week Lows

March 31 at 8:23 PM | finance.yahoo.com

Regeneron price target lowered to $1,000 from $1,100 at JPMorgan

March 31 at 5:55 PM | markets.businessinsider.com

3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space

March 31 at 10:10 AM | zacks.com

California Public Employees Retirement System Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 31 at 6:31 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
3 Defense Stocks Set to Benefit From Increased Military Spending
By Chris Markoch | March 20, 2025
View 3 Defense Stocks Set to Benefit From Increased Military Spending
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
By Jea Yu | March 11, 2025
View Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares

AMGN, REGN, GILD, and MRNA Company Descriptions

Amgen NASDAQ:AMGN

$305.70 -1.22 (-0.40%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$309.17 +3.47 (+1.14%)

As of 08:03 AM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gilead Sciences NASDAQ:GILD

$111.89 +0.61 (+0.55%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$112.01 +0.12 (+0.11%)

As of 08:02 AM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Moderna NASDAQ:MRNA

$27.72 +0.56 (+2.06%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$26.85 -0.87 (-3.14%)

As of 08:02 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals NASDAQ:REGN

$625.60 +8.60 (+1.39%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$611.30 -14.30 (-2.29%)

As of 08:02 AM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time